Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Jasmer
Robert M
RM
Daley
Charles L
CL
D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000191:economics; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000191:economics; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism; D016527:Drug Costs; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008111:Liver Function Tests; D010349:Patient Compliance; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000009:adverse effects* / Q000191:economics; D012293:Rifampin / Q000009:adverse effects* / Q000191:economics; D012307:Risk Factors; D012449:Safety; D014374:Tuberculin Test; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin